Management will conduct a conference call and audio webcast on Wednesday, November 1, 2017 at 8:30 a.m. Eastern Time to discuss these results.
NEW YORK, Oct. 25, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it will report its third quarter 2017 financial results prior to the NASDAQ market open on November 1, 2017. Intercept management will conduct a conference call and audio webcast on Wednesday, November 1, 2017 at 8:30 a.m. Eastern Time to discuss these results.
Intercept management will also be presenting at the following investor conference:
- Credit Suisse 26th Annual Healthcare Conference on November 7, 2017 at 4:30 p.m. Pacific Time
Webcast information for these events will be available on the Investors page of Intercept’s website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept’s website for approximately two weeks.
About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept now has operations in the United States, Europe and Canada.
For more information about Intercept Pharmaceuticals, please contact:
Intercept Pharmaceuticals:
Mark Vignola
+1-646-747-1000
investors@interceptpharma.com
Media inquiries: media@interceptpharma.com
Investor inquiries: investors@interceptpharma.com
